HHS OIG Outlines Safe Harbor for DTC Drug Sales
HHS’ Office of Inspector General (OIG) has issued new guidance clarifying when pharmaceutical manufacturers can sell prescription drugs directly to patients enrolled in federal health care programs without violating the federal Anti-Kickback Statute. The guidance comes as direct-to-consumer drug sales have begun to expand, including in connection with the Trump administration’s planned TrumpRx platform, which aims to connect patients with manufacturers and other private companies offering lower-cost prescription drugs outside traditional insurance channels.
The Anti-Kickback Statute is a criminal law that prohibits offering or receiving anything of value to induce referrals or purchases of items or services reimbursed by federal health care programs such as Medicare and Medicaid. Violations are felonies punishable by fines, prison time, exclusion from federal programs, and civil monetary penalties.
In a Special Advisory Bulletin, OIG says manufacturer-run direct-to-consumer (DTC) programs that offer prescription drugs at lower, cash-pay prices can present a “low risk” under the anti-kickback law if three core conditions are met: the drug is not billed to a federal health care program, the sale is not tied to the purchase of other federally reimbursable items or services, and the arrangement follows additional safeguards outlined by the agency.
Among those safeguards, OIG said patients must have a valid prescription from an independent prescriber, no insurance claims — public or private — may be submitted for the drug, and manufacturers may not use discounted DTC offerings as a marketing tool to promote other federally reimbursed products. HHS also says manufacturers should not condition discounted pricing on future purchases and should make drugs available through DTC programs for at least a full plan year.
The bulletin also cautions against so-called “seeding” practices, in which manufacturers might use discounted direct sales to encourage patients to start a therapy with the expectation that a federal health care program will later pay for it.
To reduce safety risks, OIG says manufacturers should consider mechanisms to communicate with patients’ health plans to support appropriate drug utilization review and medication therapy management. Controlled substances are excluded from the low-risk framework, and OIG says it will continue to evaluate whether other categories of drugs may raise utilization or safety concerns if offered through DTC programs.
OIG says it may seek additional public input through future rulemaking or guidance as it gains more experience with DTC drug sales models. Manufacturers and other stakeholders can also seek case-specific feedback through the agency’s advisory opinion and frequently asked questions processes.